Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Signal Transduction Pathway Deregulation”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)Looking for participantsNCT06363734
What this trial is testing

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Who this might be right for
Non-small Cell Lung CancerEGFR Activating MutationCell Cycle Deregulation+1 more
Tianjin Medical University Cancer Institute and Hospital 32
Large-scale testing (Phase 3)Looking for participantsNCT03458221
What this trial is testing

Signal TrAnsduction Pathway Activity Analysis in OVarian cancER

Who this might be right for
Recurrent Ovarian CancerSignal Transduction Pathway DeregulationTherapy-Associated Cancer
Gynaecologisch Oncologisch Centrum Zuid 148
Not applicableStudy completedNCT03488641
What this trial is testing

Systematic and Mechanism-based Approach to Rational Treatment Trials of Blood Cancer

Who this might be right for
Hematologic DiseasesTreatment
German Cancer Research Center 80
Early research (Phase 1)Study completedNCT01868022
What this trial is testing

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

Who this might be right for
Neoplasms
GlaxoSmithKline 65